IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies Leukemia (2011) Recently, recurrent somatic missense mutations in NADP þ -dependent isocitrate dehydrogenase gene (IDH1) at codon R132, as well as IDH2 at codon R172, have been identified in low-grade gliomas/secondary glioblastoma by high-throughput sequencing.
1 Subsequent studies also revealed that acquired somatic mutations in IDH1 frequently occurred in adult hematological malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 2, 3 More recently, Paschka et al. 4 reported that not only IDH1 but also IDH2 mutations occurred relatively frequently in adult AML, and that these mutations were associated with older age, poor prognosis, cytogenetically normal AML (CN-AML) and the genotype of mutated NPM1 without FLT3-internal tandem duplication (ITD). Exon 4 of both IDH1 and IDH2, which was previously identified as a hot spot for mutations in these genes, encodes three arginine residues (R100, R109 and R132 in IDH1 and R140, R149, and R172 in IDH2) that are important for protein activities. 5 Tumor-derived IDH1 and IDH2 mutations impair the affinity of enzymes for substrates, and dominantly inhibit wild-type IDH1 and IDH2 activities through the formation of catalytically inactive heterodimers. 5 Ho et al. 6 previously reported that IDH1 mutations are not detected in pediatric AML; however, little is known about the incidence and prognostic values of IDH1 and IDH2 mutations in pediatric myeloid malignancies. Here, we analyzed mutations that involve the activation sites of IDH1 and IDH2 (exon 4 and exon 7 in both IDH1 and IDH2) using genomic DNApolymerase chain reaction amplification/sequencing in a total of 199 samples of pediatric myeloid malignancies, including 17 AML-derived cell lines, 115 primary cases of AML, 28 primary cases of MDS, 15 primary cases of juvenile myelomonocytic leukemia (JMML), 6 chronic myeloid leukemia (CML)-derived cell lines and 18 primary cases of CML. Moreover, to assess whether IDH1 and IDH2 mutations overlap with known gene abnormalities, such as FLT3, c-KIT and NPM1 mutations, mutational analyses of FLT3, c-KIT and NPM1 were also performed in AML samples. This study was approved by the ethics committee of the University of Tokyo (Approval Number 3043).
The common IDH2 R140Q mutation was detected in a single AML case, whereas no IDH1 mutation including G123E, as well as no other IDH2 mutations, such as R172K, were detected in our study ( Figure 1 ). The IDH2 R140Q mutation detected in the AML case was a heterozygous substitution. No IDH1 and IDH2 mutations were detected in the JMML, MDS or CML samples examined. As the additional activation sites of both IDH1 and IDH2 are located in exon 7 of these genes, direct sequencing of exon 7 of IDH1 and IDH2 was also performed, but no mutations were detected in our series. Six AML samples including one cell line had c-KIT mutations (D816V, N822K and D419fs), and 12 AML samples had FLT3-ITD. The NPM1 mutation was detected in 2 of 132 AML samples. The AML case harboring the IDH2 mutation, case 39, showed no abnormalities of NPM1, c-KIT and FLT3. Case 39 was a 12-year-old boy diagnosed as AML-M2 according to the French-American-British cooperative group classification system. Bone marrow blasts obtained at initial diagnosis showed t(8;21)(q22;q22). After complete remission was achieved by the ACMP (adriamycin, cytarabine, 6-mercaptopurine, prednisolone) two-step induction therapy, the patient underwent consolidation therapy every 5 weeks, but hematological relapse occurred 11 months after the initial diagnosis. He was treated with low-dose cytarabine, but died 5 months after relapse with progressive disease. To assess the genetic mechanisms involved in the pathogenesis of the disease of this case, we further performed genome-wide copy number analysis of bone marrow blasts obtained at initial diagnosis of this case, using single-nucleotide polymorphism (SNP)-genotype microarrays (Affymetrix GeneChip Mapping 250 K StyI arrays, 
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Affymetrix, Inc., Santa Clara, CA, USA). As shown in Figure 2 , complex chromosomal abnormalities, such as heterozygous deletions at chromosomes 7q11.2, 7q34-qter, 9q13-q21.33, 9q22.33, 16q23.1-q24.3 and 17q12qter, as well as gains of 4q24.3, 17q12-qter and 22q12.3-q13.33 were detected in leukemic cells of this patient (Figure 2 ).
To our knowledge, this is the first report to describe the IDH2 mutation in a pediatric AML patient. In the present study, we detected the IDH2 R140Q mutation in a single AML case out of 199 samples of pediatric myeloid malignancies, which suggests that the involvement of IDH1 and IDH2 mutations in the pathogenesis of pediatric AML is extremely rare compared with those in adult AML cases. Likewise, although IDH mutations are frequently observed in adult brain tumors, they are not observed in pediatric cases. 1 Therefore, somatically acquired IDH1 and IDH2 mutations may be related to an acquired neoplastic pathway exclusive to adult patients. Several groups have reported that IDH1 and IDH2 mutations are significantly associated with a normal karyotype in adult AML. 4, 6 However, our patient with an IDH2 mutation had t(8;21) together with complex chromosomal changes. Furthermore, a previously reported genome-wide study of pediatric AML revealed that, in contrast to our AML patients with IDH2 mutation, pediatric de novo AML was characterized by a very low burden of genomic alterations. 7 These clinical and cytogenetic data suggest that pediatric AML with t(8;21) and IDH2 mutation might be a specific subtype of AML with complex chromosomal abnormalities and poor prognosis. Thus, our result has important clinical and pathological implications regarding the role of IDH2 mutations in the development of AML. t(8;21) is considered as a distinct AML subtype associated with characteristic morphology and a favorable prognosis. 8 Although approximately 90% of AML patients with t(8;21) achieve remission, relapse is frequent. 8 Once the disease relapses, the prognosis is poor, with an overall survival of 50% at 5 years. 8 Although the c-KIT mutation and FLT3-ITD are considered as poor prognostic factors in AML patients with t(8;21), these abnormalities occur in approximately 10% of AML patients with t(8;21). 9 Notably, IDH1 and IDH2 mutations constitute a poor prognostic factor in CN-AML with mutated NPM1 without FLT3-ITD, which allows refined risk stratification of this AML subset. 4 Although treatment contents as well as clinical and genetic backgrounds were some of the parameters influencing the patient's outcome, our findings suggest that the IDH2 mutation may also be related to an inferior outcome in pediatric AML patients with t(8;21) even if they lack the c-KIT mutation and FLT3-ITD. As IDH2 mutation with t(8;21) is an extremely rare event and the prognostic values of IDH2 mutations in AML Figure 2 The result of copy number analysis using SNP-genotyping microarrays. (a) The moving average of the total copy number plot is presented. Each chromosome is indicated by different colors. Deletions in the regions at 7q, 9q, 16q and 17q, and gains in the region at 12q, 17q and 22q are indicated by the red arrows. (b) Deletions of 7q, 9q, 16q and 17q, and gains of 12q, 17q and 22q. The total copy number plot from each probe (red points) and the moving average (blue line) are shown above the cytobands. The results of the allele-specific analysis with CNAG/ AsCNAR are shown below the cytobands. The larger allele is presented in red, and the smaller allele is presented in green. The numbers located at the left edge of each lane indicate a normal copy number (2 for total copy number analysis and 1 for allele-specific copy number analysis).
Letters to the Editor with t(8;21) are still unclear, further data accumulation is necessary. Although uncommon in pediatric myeloid malignancies, IDH1 and IDH2 mutations, particularly IDH2 mutations, could contribute to the advanced phenotype of AML. Our findings provide additional impetus for investigating the role of IDH1 and IDH2 in the pathophysiology of errors of metabolism and in neoplastic disorders.
